Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine

Clinical Pharmacology and Therapeutics

Volumn 74, Issue 5, 2003, Pages 423-436

  Tannergren, Christer ^b   Petri, Niclas ^b   Knutson, Lars ^b   Hedeland, Mikael ^b   Bondesson, Ulf ^b   Lennernäs, Hans ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CARBON 14; CARRIER PROTEIN; CYTOCHROME P450 3A; ERYTHROMYCIN; FEXOFENADINE; GLYCOPROTEIN P; KETOCONAZOLE; LIDOCAINE; MACROGOL 4000; MEMBRANE PROTEIN; PHENAZONE; RIFAMPICIN; TROGLITAZONE; VERAPAMIL;

ADULT; ANION TRANSPORT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG PENETRATION; DRUG TRANSPORT; DRUG UPTAKE; FEMALE; FIRST PASS EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; INTESTINE ABSORPTION; INTRAHEPATIC BILE DUCT; JEJUNUM; LIVER SINUSOID; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN FUNCTION; TRANSPORT KINETICS; ULTRAVIOLET SPECTROSCOPY;

ADULT; ALGORITHMS; ANTI-ALLERGIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CALCIUM CHANNEL BLOCKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; INTESTINAL ABSORPTION; INTESTINES; JEJUNUM; MALE; MEMBRANE TRANSPORT MODULATORS; MEMBRANE TRANSPORT PROTEINS; REGIONAL BLOOD FLOW; SPECTROPHOTOMETRY, ULTRAVIOLET; TERFENADINE; VERAPAMIL;

EID: 0242351210     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(03)00238-8     Document Type: Article

References (48)

1. Borst P, Elferink RO. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002;71:537-92.
2. Meier PJ, Stieger B. Bile salt transporters. Annu Rev Physiol 2002;64:635-61.
3. Tucker GT, Houston JB, Huang SM. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - towards a consensus. Br J Clin Pharmacol 2001;52:107-17.
4. Kok T, Wolters H, Bloks VW, Havinga R, Jansen PLM, Staels B, et al. Induction of hepatic ABC transporter expression is part of the PPARα-mediated fasting response in the mouse. Gastroenterology 2003;124:160-71.
5. Lennernäs H, Ahrenstedt Ö, Hällgren R, Knutsson L, Ryde M, Paalzow L. Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man. Pharm Res 1992;9:1243-51.
6. Lennernäs H. Human intestinal permeability. J Pharm Sci 1998;87:403-10.
7. von Richter O, Greiner B, Fromm MF, Fraser R, Omari T, Barclay ML, et al. Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique. Clin Pharmacol Ther 2001;70:217-27.
8. Gramatte T, Oertel R. Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil. Clin Pharmacol Ther 1999;66:239-45.
9. Lennernäs H, Lee I-D, Fagerholm U, Amidon GL. A residence-time distribution analysis of the hydrodynamics within the intestine in man during a regional single-pass perfusion with Loc-I-Gut: in vivo permeability estimation. J Pharm Pharmacol 1997;49:682-6.
10. Amidon GL, Lennernäs H, Shah VP, Crison J. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12:413-20.
11. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 1999;27:866-71.
12. Lippert C, Ling J, Brown P, Burmaster S, Eller M, Cheng L, et al. Mass balance and pharmacokinetics of MDL 16,455A in healthy male volunteers [abstract]. Pharm Res 1996;12:S390.
13. Putnam WS, Ramanathan S, Pan L, Takahashi LH, Benet LZ. Functional characterization of monocarboxylic acid, large neutral amino acid, bile acid and peptide transporters, and P-glycoprotein in MDCK and Caco-2 cells. J Pharm Sci 2002;91:2622-35.
14. Perloff MD, von Moltke LL, Greenblatt DJ. Fexofenadine transport in Caco-2 cells: inhibition with verapamil and ritonavir. J Clin Pharmacol 2002;42:1269-74.
15. Simpson K, Jarvis B. Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs 2000;59:301-21.
16. Davit B, Reynolds K, Yuan R, Ajayi F, Conner D, Fadiran E, et al. FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labeling. J Clin Pharmacol 1999; 39:899-910.
17. Hamman MA, Bruce MA, Haehner-Daniels BD, Hall SD. The effect of rifampin administration on the disposition of fexofenadine. Clin Pharmacol Ther 2001;69: 114-21.
18. Gupta S, Banfield C, Kantesaria B, Marino M, Clement R, Affrime M, et al. Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study. Clin Ther 2001;23:451-66.
19. Wang Z, Hamman MA, Huang SM, Lesko LJ, Hall SD. Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 2002;71:414-20.
20. Dresser GK, Schwarz UI, Wilkinson GR, Kim RB. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin Pharmacol Ther 2003;73:41-50.
21. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001;70:189-99.
22. Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, et al. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther 2002;71:11-20.
23. Drescher S, Schaeffeler E, Hitzl M, Hofmann U, Schwab M, Brinkmann U, et al. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 2002;53:526-34.
24. Tannergren C, Knutson T, Knutson L, Lennernäs H. The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. Br J Clin Pharmacol 2003;55:182-90.
25. Winiwarter S, Bonham NM, Ax F, Hallberg A, Lennernäs H, Karlén A. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. J Med Chem 1998;41:4939-49.
26. Lindahl A, Sandström R, Ungell A-L, Abrahamsson B, Knutson T, Knutson L, et al. Jejunal permeability and hepatic extraction of fluvastatin in humans. Clin Pharmacol Ther 1996;60:493-503.
27. Sandström R, Knutson TW, Knutson L, Jansson B, Lennernäs H. The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans. Br J Clin Pharmacol 1999;48:180-9.
28. Russell T, Stoltz M, Weir S. Pharmacokinetics, pharmacodynamics, and tolerance of single-and multiple-dose fexofenadine hydrochloride in healthy male volunteers. Clin Pharmacol Ther 1998;64:612-21.
29. Knutson L, Odlind B, Hallgren R. A new technique for segmental jejunal perfusion in man. Am J Gastroenterol 1989;84:1278-84.
30. Sandström R, Karlsson A, Knutson L, Lennernäs H. Jejunal absorption and metabolism of R/S-verapamil in humans. Pharm Res 1998;15:856-62.
31. Sandström R, Lennernäs H, Ohlen K, Karlsson A. Enantiometric separation of verapamil and norverapamil using Chiral-AGP as the stationary phase. J Pharm Biomed Anal 1999;21:43-9.
32. Wagner JG, Nelson E. Kinetic analysis of blood levels and urinary excretion in the absorptive phase after single doses of drug. J Pharm Sci 1964;53:1392-403.
33. Ito K, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 1998;50:387-411.
34. Lemma GL, Hamman MA, Hall SD, Wang Z. The effect of verapamil administration on the pharmacokinetics of fexofenadine [abstract]. Clin Pharmacol Ther 2003;73: P16.
35. Chiou WL, Chung SM, Wu TC, Ma C. A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. Int J Clin Pharmacol Ther 2001;39:93-101.
36. Tamai I, Nezu J, Uchino H, Sai Y, Oku A, Shimane M, et al. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 2000; 273:251-60.
37. Walters HC, Craddock AL, Fusegawa H, Willingham MC, Dawson PA. Expression, transport properties, and chromosomal location of organic anion transporter subtype 3. Am J Physiol Gastrointest Liver Physiol 2000; 279:G1188-200.
38. Kelder J, Grootenhuis PD, Bayada DM, Delbressine LP, Ploemen JP. Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs. Pharm Res 1999;16:1514-9.
39. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res 1999;16:408-14.
40. 14C]verapamil in man. Drug Metab Dispos 1979;7:145-8.
41. Pauli-Magnus C, von Richter O, Burk O, Ziegler A, Mettang T, Eichelbaum M, et al. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther 2000;293: 376-82.
42. Hedman A, Angelin B, Arvidsson A, Beck O, Dahlqvist R, Nilsson B, et al. Digoxin-verapamil interaction: reduction of biliary but not renal digoxin clearance in humans. Clin Pharmacol Ther 1991;49:256-62.
43. Lindahl A, Persson B, Ungell A-L, Lennernäs H. Surface activity and concentration dependent intestinal permeability in the rat. Pharm Res 1999;16:97-102.
44. Yamashita S, Yoshida M, Taki Y, Sakane T, Nadai T. Kinetic analysis of the drug permeation process across the intestinal epithelium. Pharm Res 1994;11:1646-51.
45. Milne RW, Larsen LA, Jorgensen KL, Bastlund J, Stretch GR, Evans AM. Hepatic disposition of fexofenadine: influence of the transport inhibitors erythromycin and dibromosulphothalein. Pharm Res 2000;17:1511-5.
46. Hellriegel ET, Bjornsson TD, Hauck WW. Interpatient variability in bioavailability is related to the extent of absorption: implications for bioavailability and bio-equivalence studies. Clin Pharmacol Ther 1996;60: 601-7.
47. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000;97:3473-8.
48. Nishizato Y, Ieiri I, Suzuki H, Kimura M, Kawabata K, Hirota T, et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 2003;73: 554-65.